Financial Statements

Apellis Pharmaceuticals Inc.

Apellis Pharmaceuticals Inc. (APLS)


Balance Sheet Statement

Download APLS income statement Download APLS income statement
Year 2015201620172018
Cash and cash equivalents 36.0024.86175.64176.27
Short-term investments ----
Cash and short-term investments 36.0024.86175.64176.27
Receivables ----
Inventories ----
Property, Plant & Equipment Net ---0.98
Goodwill and Intangible Assets ----
Long-term investments ----
Tax assets ----
Total non-current assets --26.6325.54
Total current assets
Total assets 38.1827.43182.13203.53
Payables 2.482.553.6610.25
Short-term debt ---1.67
Total current liabilities 3.203.646.5517.02
Long-term debt --26.3925.38
Total debt --26.3927.04
Deferred revenue ----
Tax Liabilities ----
Deposit Liabilities ----
Total non-current liabilities --26.6325.54
Total liabilities 3.203.6433.1942.56
Other comprehensive income ----0.12
Retained earnings (deficit) -71.13-98.26-149.26-276.77
Total stockholders equity ----
Investments ----
Net Debt -36.00-24.86-149.25-149.22
Other Assets 2.042.516.3726.17
Other Liabilities 0.721.092.895.10

Apellis Pharmaceuticals Inc. income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes Apellis Pharmaceuticals Inc. FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.